Cisplatin transmucosal patch - Privo Technologies

Drug Profile

Cisplatin transmucosal patch - Privo Technologies

Alternative Names: PRV 111

Latest Information Update: 25 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Privo Technologies
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Orofacial cancer

Most Recent Events

  • 25 Jul 2018 Chemical structure information added
  • 19 Jun 2018 Phase-I/II clinical trials in Orofacial cancer in USA (Transmucosal) (NCT03502148)
  • 18 Apr 2018 Privo Technologies plans a phase I/II trial for Squamous cell carcinoma in USA , (NCT03502148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top